Adagio Medical (ADGM) Projected to Post Earnings on Wednesday

Adagio Medical (NASDAQ:ADGM) is anticipated to release its Q3 2026 results before the market opens on Wednesday, November 11th. Analysts expect Adagio Medical to post earnings of ($0.2467) per share for the quarter. Parties may visit the company’s upcoming Q3 2026 earnings report for the latest details on the call scheduled for Wednesday, November 11, 2026 at 9:30 AM ET.

Adagio Medical (NASDAQ:ADGM) last posted its quarterly earnings results on Tuesday, August 11th. The company reported ($0.30) EPS for the quarter, missing analysts’ consensus estimates of ($0.27) by ($0.03). On average, analysts expect Adagio Medical to post ($1.25) EPS for the current fiscal year and ($1.75) EPS for the next fiscal year.

Adagio Medical Price Performance

Adagio Medical stock opened at $0.09 on Wednesday. Adagio Medical has a 12 month low of $0.08 and a 12 month high of $1.69. The company has a current ratio of 1.41, a quick ratio of 1.15 and a debt-to-equity ratio of 4.00. The business’s 50 day simple moving average is $0.29 and its 200 day simple moving average is $0.74. The company has a market cap of $2.37 million, a price-to-earnings ratio of -0.06 and a beta of 0.07.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings downgraded Adagio Medical from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Wednesday, August 19th. Two investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $3.50.

Adagio Medical Company Profile

Adagio Medical, Inc is a medical technology company focused on developing catheter-based treatments for cardiac arrhythmias, including atrial fibrillation. The company’s technology is designed to create continuous, transmural lesions in cardiac tissue to isolate abnormal electrical signals and help restore a normal heart rhythm.

Its lead platform is the Intelligent Continuous Lesion Ablation System (iCLAS), an ultra-low-temperature cryoablation system intended to treat atrial fibrillation and other heart rhythm disorders.